1. Home
  2. WVE vs HCM Comparison

WVE vs HCM Comparison

Compare WVE & HCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Wave Life Sciences Ltd.

WVE

Wave Life Sciences Ltd.

HOLD

Current Price

$12.65

Market Cap

2.4B

Sector

Health Care

ML Signal

HOLD

Logo HUTCHMED (China) Limited

HCM

HUTCHMED (China) Limited

HOLD

Current Price

$14.76

Market Cap

2.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WVE
HCM
Founded
2012
2000
Country
Singapore
Hong Kong
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.4B
2.7B
IPO Year
2015
N/A

Fundamental Metrics

Financial Performance
Metric
WVE
HCM
Price
$12.65
$14.76
Analyst Decision
Strong Buy
Sell
Analyst Count
16
1
Target Price
$30.44
$13.75
AVG Volume (30 Days)
3.2M
32.2K
Earning Date
03-03-2026
03-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.53
Revenue
$109,230,000.00
$602,197,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$16.10
$15.54
P/E Ratio
N/A
$5.39
Revenue Growth
103.75
N/A
52 Week Low
$5.28
$11.51
52 Week High
$21.73
$19.50

Technical Indicators

Market Signals
Indicator
WVE
HCM
Relative Strength Index (RSI) 41.05 48.84
Support Level $12.51 $14.58
Resistance Level $14.15 $15.25
Average True Range (ATR) 0.76 0.39
MACD -0.04 -0.07
Stochastic Oscillator 8.29 45.11

Price Performance

Historical Comparison
WVE
HCM

About WVE Wave Life Sciences Ltd.

WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.

About HCM HUTCHMED (China) Limited

HUTCHMED (China) Ltd is an biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.

Share on Social Networks: